Whilst gene‐specific therapies currently do not exist for glaucoma, some studies have shown promising results to improve the glaucoma phenotype in MYOC mice models using either chemical chaperones (phenylbutyrate) or CRISPR genome editing [86, 87]. This evidence concerns the gene MYOC and glaucoma.